Live from NPR News in Washington, I'm Janine Herbst.
President Trump has imposed new 10 to 12 and 1/2 percent tariffs against 59 countries,
“plus the European Union, claiming those economies import goods with forced labor.”
This after the Supreme Court struck down other tariffs earlier this year. The U.S. trade representative says it covers countries responsible for 99 percent of all U.S. imports, but it does exempt energy and some food products. Here's Daniel Kurtz-Lavin has more. Whole after poll shows that Americans don't like the tariffs, and that they're
approval of the President on the economy has fallen. But whether or not Americans like them, we know the President likes tariffs. He sees them as a way to strong our mother countries during trade negotiations. And his administration maintains that tariffs will have long-term economic benefits. Now, plenty of economists would dispute that, but all in all, these are a gamble.
They're asking voters to weigh a policy they might not like against what might happen in the future. And here's Daniel Kurtz-Lavin reporting. The State Department is seeking more information about the financial dealings of an Iranian business conglomerate tied to the weapons industry.
It's offering up to $15 million for information as NPR's Michelle Kelliman reports.
According to the State Department, the Iranian business conglomerate, Bejo O'Pars, or BJP,
“plays an important role in Iranian missile production, and has tried to procure sensitive”
materials through front companies around the world. The U.S. has already revoked about a hundred visas of people linked to these business dealings, and now it has added two more employees to a reward for justice announcement. It's asking Iranians to come forward with information in exchange for up to $15 million or possible relocation to the United States.
To other BJP executives had already been put on the rewards for Justice wanted list. Michelle Kelliman and B.R. News, the State Department. The Justice Department has agreed to drop subpoenas against journalists at the New York Times, a mid-questioning by a federal judge, and Piers David Folkanflick says the issue involved the source of leaks about the new Air Force One jet given to the U.S. by Qatar.
U.S. judge Arun Submarinian fired off a series of questions for which the lead prosecutor in the case Sean Buckley had no satisfactory answers. The judge said the government had failed to observe legally required safeguards for reporters and had misled the court.
“Buckley cited over-sites and said no bad faith was involved, he also apologized for”
subpoenaing the phone records of reporters' family members calling that a mistake. But Buckley defended the subpoenas as legitimate, saying the approval of the acting attorney general overruled journalistic protections. New York Times lawyer David McCraught tells NPR the federal court stepped up to defend
the first amendment and the rule of law.
David Folkanflick, NPR News U.S. futures contracts at trading in mixed territory at this hour, you're listening to NPR News from Washington. U.S. shooting in Madison with Wisconsin Wednesday is being investigated as a homicide. Police Chief John Patterson says it happened as officers were trying to arrest a man identified
as Cory Rees, whom they say tried to flee on a bike that allegedly pulled a knife as police tried to subdue him. Reports of the struggle were recorded by a passerby and appeared to show police fired shots after Rees was already on the ground. Patterson declined to name the officer involved, but said that officer was placed on administrative
leave, along with others. Eli Lilly's new experimental obesity drug is getting closer to the finish line. The company says it will submit the medicine to the FDA for approval next year. Pair Sydney Lopkin has more, Eli Lilly is studying retratroutide, which is part of the next generation of obesity drugs currently being studied.
While Wigovie and Zephound target the GLP-1 hormone, this new drug works on three hormones, GLP-1, GIP and Glucagan. New trial results show patients with severe obesity and cardiovascular disease, taking the highest dose of retratroutide lost up to an average of 56 pounds over 80 weeks, and patients with obesity and type 2 diabetes lost up to an average of 50 over the same time.
Eli Lilly says it plans to submit the findings to a peer-reviewed medical journal. And although the company had said in May that it was aiming to submit retratroutide for FDA approval by the end of the year, it now says it will do so in the first three months of 2027. City Lopkin and Pair News.
You're listening to NPR News. The last time Antonio May's senior heard from his son, it was in a note the 16-year-old left in the family's garage. He told me he was going to make me cry. Antonio Junior left home to join a protest in Seattle.
A week later, he was shot and killed there. I need some a ref made, just as for my son.
